[1]
A. Jewett, “First in Human Clinical Study Demonstrating the Safety and Efficacy of NK101 (supercharged NK cells) in the Treatment of Patients with Cancer”, SEE J Immunol, vol. 8, no. CITIM, p. 040, Mar. 2025.